BTX - Brooklyn Immuno wins Bullish views at Cantor; sees a potential partnership

Cantor Fitzgerald has started the coverage on Brooklyn ImmunoTherapeutics (BTX -2.9%) with an Overweight recommendation arguing that the company could attract a partnership for its experimental cancer therapy IRX-2. IRX?2, a mixed, human-derived cytokine product, is currently undergoing studies targeting several types of cancer. A Phase 2B study called INSPIRE study involving patients with squamous cell cancer of the head and neck is set to generate topline data in H2 2022. The positive data read could lead to “a partnership” the analyst Kristen Kluska projects, estimating a price target of $9 for the stock, a premium of ~98.7% to the last close. In addition, the firm highlights the preclinical data for the company’s lipid nanoparticle and mRNA-based gene-editing platforms, which, according to the analyst, could support its allogeneic stem-cell programs with a potential first-in-human study in Q4 2023. Brooklyn ImmunoTherapeutics (NASDAQ:BTX) has traded flat over the year, and last month

For further details see:

Brooklyn Immuno wins Bullish views at Cantor; sees a potential partnership